KRISTINA SPITALE-EFSTRATIS: Open Payments
NPI 1225532542 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,025 in 40 payments from 18 companies in 2025. Trend: 2023 $553 · 2024 $610 · 2025 $1,025
Food & beverage: $969Education: $56
| Company | Payments | Amount |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 6 | $234 |
| Travere Therapeutics, Inc. | 5 | $157 |
| GENZYME CORPORATION | 4 | $95 |
| Novartis Pharmaceuticals Corporation | 3 | $79 |
| Amgen Inc. | 3 | $79 |
| OPKO Pharmaceuticals, LLC | 3 | $56 |
| GlaxoSmithKline, LLC. | 3 | $54 |
| Novo Nordisk Inc | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Resmed Corp | 1 | $27 |
Products named: DUPIXENT, Filspari, Fabhalta, KRYSTEXXA, RAYALDEE, Ozempic, JYNARQUE, NUCALA.
Industry payments across NV — which companies pay providers there.
